Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, a...

by Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying
Published 2020-07-01

Oncology education for family medicine residents: a national needs assessment survey

by Steven M. Yip, Daniel E. Meyers, Jeff Sisler, Keith Wycliffe-Jones, Edward Kucharski, Christine Elser, Claire Temple-Oberle, Silvana Spadafora, Paris-Ann Ingledew, Meredith Giuliani, Sara Kuruvilla, Nureen Sumar, Vincent C. Tam
Published 2020-08-01

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database

by Haider H. Samawi, Hao‐Wen Sim, Kelvin K. Chan, Mohammad A. Alghamdi, Richard M. Lee‐Ying, Jennifer J. Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo‐Joung Ko, Janine M. Davies, Howard J. Lim, Winson Y. Cheung, Vincent C. Tam, the CHORD Consortium
Published 2018-07-01

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

by Mohammed A. Alghamdi, Carla P. Amaro, Richard Lee‐Ying, Hao‐Wen Sim, Haider Samwi, Kelvin K. Chan, Jennifer J. Knox, Yoo‐Joung Ko, Mina Swiha, Eugene Batuyong, Adriana Romagnino, Winson Y. Cheung, Vincent C. Tam, the Hepatocellular Carcinoma ‐ Cancer Health Outcomes Research Database (HCC ‐ CHORD) Consortium
Published 2020-07-01